Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Journeytcon Jul 11, 2024 2:22pm
229 Views
Post# 36128794

Request for ONC to Update Guidance

Request for ONC to Update GuidanceIm recommending shareholders message ONC on their website requesting update on Breast Cancer upcoming milestones.   The typee C meeting concluded and they have not updated guidance. 
1.  When do rhey expect to file for approval of the phase 3 breast cancer trial?
2.  Are they awaiting additional data or conclusion of the Bracelet trial before doing so?
3.  When do they expect first enrollment in the phase?
4.  What is the target population for the therapeutic?   What does including upto first ADC treatment mean?  Are they expecting to be the frontline treatment of choice?

To message go to oncolytic biotechs website and under contact they give opportunity for inquiry.



<< Previous
Bullboard Posts
Next >>